Net Equity Supply Turns Positive: The SpaceX Lockup Cliff and 2026's Issuance Test

The Inflection Point Nobody Announced

The most important shift in US equity markets in the first half of 2026 was not a single deal, a Fed decision, or an earnings beat. It was a line crossing zero.

Federal Reserve Flow of Funds data released in June showed net equity supply swinging from a negative $216 billion annualized pace in the fourth quarter of 2025 to a positive $124 billion pace in the first quarter of 2026 — the first time US equity supply has been net positive since 2021.^[1] For roughly two decades, American corporations bought back more stock than they issued, shrinking the supply of publicly traded shares and creating a structural tailwind that supported prices. That tailwind is now fading, and the market is being asked to absorb new paper at a pace not seen since the dot-com era.

JPMorgan estimates that net equity issuance could reach $1.2 trillion by 2027 if current trends hold.^[2] That is a forecast, not a fact — but the trajectory is clear. The combination of AI-driven capital expenditure demands, a record IPO pipeline, and moderating buyback activity is reversing what strategists called “de-equitization.” The market’s biggest buyer — corporate America itself — is stepping back just as the supply faucet opens wider.

H1 2026 by the Numbers

The first half of 2026 delivered issuance volumes that put the post-2021 drought firmly in the rearview mirror.

Follow-on offerings — secondaries, blocks, and capital raises by already-public companies — accounted for the majority of deal volume, a sign that the issuance wave is not just about new listings. Seasoned issuers are tapping markets at scale. Morgan Stanley reported that global equity capital markets issuance rose 43% year over year to $256.8 billion in the first quarter alone, with IPO volumes up 40% to $45 billion.^[5]

Wall Street’s underwriting desks are reaping the windfall. Goldman Sachs reported its highest investment banking backlog in five years — its second-highest level on record — while JPMorgan’s CFO Jeremy Barnum described a pipeline where “the high-profile nature of the activity this quarter… is itself begetting more activity.”^[6] Goldman CEO David Solomon said he expects “this flywheel of activity to continue.”^[6]

Whether that flywheel sustains itself depends on a question that strategists have been asking since the IPO window reopened: Can markets absorb the supply? Academic research has shown surging equity issuance to be something of an indicator of the later stages of market booms, with the surge in stock issuance in the late 1990s and early 2000s — which hit the market with a delay as lockup restrictions expired — cited as a key contributor to the dot-com crash.^[6]

The SpaceX Lockup Cliff

SpaceX’s IPO was the largest in history. The company priced at $135 per share on June 11, raising approximately $75 billion in its base offering (reported as $86.2 billion including the exercised overallotment option), at a valuation of roughly $1.77 trillion.^[4] The stock surged to an intraday high near $225.64 on June 16 before reversing sharply.^[7] As of the July 24 close, SPCX traded at $115.07 — below its IPO price and down roughly 49% from its peak.^[8]

The next inflection point is now days away. SpaceX will report its first-ever quarterly earnings after market close on August 4.^[7] Two days later, on August 6, the first tranche of its staged lockup expires, freeing approximately 911.5 million shares — worth roughly $116 billion at recent prices — for trading.^[7] That single tranche is roughly 68 times the typical lockup size for large-cap IPOs, and larger than the entire $75 billion SpaceX raised in its offering.^[7]

SpaceX’s lockup is not a standard 180-day cliff. It is a staggered structure designed to release shares gradually and avoid major disruptions to market supply and demand:

Sources: MLQ News^[7], EquiLend^[4]

The second tranche — 455.8 million shares — would unlock only if the stock traded at or above $175.50 for five of ten consecutive trading days through the earnings date.^[7] With SPCX trading more than 30% below that threshold, that tranche appears unlikely to trigger.^[7] Elon Musk’s 6.4 billion shares and a broader extended-investor block representing more than 63% of pre-IPO shares remain locked until at least Q1 2027, with Musk’s personal stake restricted until June 2027.^[4]

The forecast here is not that August 6 produces a crash. It is that the event is without historical precedent — the $116 billion first tranche dwarfs any prior lockup expiration in US equity markets^[7] — which means the range of outcomes is genuinely wide. A 60/40 read: roughly 60% probability that the unlock produces orderly selling absorbed by pent-up demand (27 of 33 covering analysts rate SPCX a buy or strong buy with a median price target of $226, implying substantial upside from current levels)^[7], and roughly 40% that the combination of below-IPO-price trading, heavy short interest (over 38% of float on loan as of July 10)^[4], and the sheer scale of newly freed shares produces a disorderly tape that pressures the stock toward the $100 level. The 40% case matters because lockup expirations have historically been a negative-drift event for newly public companies, and the scale here amplifies whatever signal exists.

Securities Finance: The Borrow Story Beneath the Tape

The issuance wave has also reshaped the securities lending market. Global securities lending revenue hit a record $9.1 billion in H1 2026, up 34% year over year, as elevated volatility around AI stocks, biotech catalysts, and new listings kept short sellers engaged.^[4] Three listings tell distinct borrow stories.

Cerebras (CBRS): The largest semiconductor IPO on record raised $5.55 billion at $185 per share on May 14, opening the next morning at $350.^[4] Short sellers moved immediately — 1.55 million shares were on loan by the first full trading day, with fees in the several-hundred-basis-point range.^[4] By June 30, utilization exceeded 90% and more than half the float was on loan, with on-loan value reaching approximately $3.8 billion.^[4] As of July 24, CBRS closed at $199.12,^[8] above its $185 IPO price but well off its opening-day high — a story of persistent short conviction even as the stock stabilized.

Quantinuum (QNT): The first major quantum computing company to go public raised $1.68 billion at $60 per share on June 4.^[4] The reception above the tape was muted — the stock slipped below its IPO price within days.^[4] But beneath the tape, Quantinuum was immediately one of the hottest borrows in the market, with fees exceeding 1,000 basis points on day one.^[4] As of July 24, QNT closed at $52.29, below its $60 IPO price.^[8] The enduring fee levels — still in the low-to-mid hundreds of basis points through July — suggest a structurally hard-to-borrow name where the short thesis has not dissolved despite a partial stock recovery.^[4]

SpaceX (SPCX): The borrow story is structurally different. Initial fees dropped below 50 basis points within days as supply entered the market,^[4] but short interest built at a remarkable pace — shares on loan expanded from 18.6 million on June 15 to over 211 million by July 10, an eleven-fold increase in under four weeks, with on-loan value reaching approximately $30.7 billion.^[4] SpaceX became a top-20 US equity lending revenue earner in June despite IPO’ing halfway through the month.^[4]

The Pipeline Narrows — but Remains Consequential

The H2 2026 pipeline has thinned since the start of the year, but the remaining names are large enough to matter on their own.

Anthropic confidentially filed on June 1 and remains on track for a late-2026 debut, with its most recent private funding round implying a valuation approaching $965 billion.^[4] Prediction markets currently price an Anthropic listing before year-end at roughly 75%.^[4] Should it proceed, the scale and investor fascination could generate borrow dynamics rivaling SpaceX, particularly if initial supply is constrained.^[4]

OpenAI presents a more complicated picture. Despite filing confidentially on June 8 and initially targeting a Q3 or Q4 listing at a valuation approaching $1 trillion, the company is reportedly leaning toward a delay into 2027 rather than accept a valuation below $1 trillion.^[4][9] Market observers have linked the recalibration in part to SpaceX’s post-IPO price action, which has underwhelmed relative to opening-day levels.^[4]

Databricks has effectively removed itself from the 2026 conversation. CEO Ali Ghodsi explicitly ruled out a listing this year, citing a crowded slate of large technology offerings; 2027 is now the market consensus.^[4]

SK Hynix completed the largest foreign US IPO in history on July 10, raising $26.5 billion in an ADR listing on Nasdaq at $149 per share, surpassing Alibaba’s 2014 record of approximately $25 billion.^[10] The Korean memory chip giant’s ADRs opened at $170, 14% above the offer price.^[10]

For securities finance practitioners, the IPO-to-lending-revenue lag observed in prior cycles — where the most intense borrow activity often arrives three to nine months post-listing — means the full revenue impact of the H1 cohort will likely not be felt until well into 2026 and 2027.^[4]

Exchange Rule Changes: The Plumbing Adjusts

While the issuance wave dominates headlines, exchanges have been quietly updating the rules that govern who gets to list and who gets to stay listed.

Nasdaq’s $5 million continued listing requirement: On July 22, the SEC approved Nasdaq’s proposal to adopt a new Market Value of Listed Securities (MVLS) continued listing requirement of at least $5 million, applicable to companies on the Nasdaq Global Select Market, Nasdaq Global Market, and Nasdaq Capital Market.^[11] Companies that fall below the threshold will face delisting proceedings under the Rule 5800 Series.^[11] The rule adds a quantitative floor to existing continued listing standards and could catch smaller or struggling issuers that maintain bid price and holder count criteria but have seen market value erode.

Nasdaq SPAC listing requirements: In April 2026, the SEC approved Nasdaq’s proposal to increase initial listing requirements for acquisition companies (SPACs) under Listing Rule IM-5101-2.^[12] The change raises the bar for new SPAC formations at a time when the IPO market has shifted toward operating companies rather than blank-check vehicles.

Nasdaq delist authority for SEC-suspended securities: In June 2026, the SEC approved Nasdaq Rule IM-5101-4, giving the exchange authority to delist a security where the SEC has previously suspended trading and the exchange determines delisting is appropriate and in the public interest.^[12]

NYSE American listing standards: In March 2026, the SEC approved amendments to the initial listing standards in Sections 101 and 102 of the NYSE American Company Guide, adjusting the requirements for companies listing on that exchange tier.^[12]

What to Watch Next

The remainder of 2026 is, in many ways, a SpaceX lockup calendar. But it is also a test of whether the market’s absorption capacity matches the supply being thrown at it. Here is the checklist:

1. August 4 — SpaceX Q2 earnings (after market close). The first detailed look at Starlink profitability, Falcon 9 launch margins, and AI infrastructure spending. The stock trades at approximately 49 times expected revenue, leaving little margin for execution missteps.^[7]

2. August 6 — First SpaceX lockup tranche (~911.5 million shares, ~$116 billion). The largest lockup expiration in financial history. Watch for selling pressure, borrow fee shifts, and whether the price-contingent second tranche threshold ($175.50) comes into play.^[7]

3. Late August through October — Rolling 7% SpaceX unlock tranches. August 31, September 10, September 25, October 10, and October 25 each release additional supply.^[7] The cumulative effect of staggered unlocks will reveal whether selling pressure is front-loaded or distributed.

4. Post-Q3 earnings — 28% SpaceX tranche. A larger block unlocks two days after SpaceX’s Q3 report, with all remaining shares fully freed by December 9, 2026.^[7]

5. Anthropic IPO timing. Prediction markets price a 2026 listing at approximately 75%.^[4] A confirmation of filing or a pricing date would add another mega-cap listing to the H2 pipeline.

6. OpenAI’s listing decision. A delay into 2027 would remove the largest potential H2 deal from the calendar and signal that the SpaceX tape has spooked other mega-issuers.^[4]

7. Net equity supply trend. The next Fed Flow of Funds release will show whether Q2 2026 continued the positive supply trend. If net issuance accelerates beyond the $124 billion annualized pace seen in Q1,^[1] the de-equitization reversal thesis strengthens.

8. Buyback pace. If corporate repurchase activity continues to moderate alongside rising issuance, the market loses a key structural support at the same time new supply arrives.^[1] Watch S&P 500 buyback announcements during Q3 earnings season.

9. Nasdaq $5M MVLS enforcement. The newly approved continued listing requirement takes effect for compliance monitoring. Companies with eroded market value that previously maintained listing status through bid-price and holder-count criteria alone face a new quantitative floor.^[11]

The base case is that the market absorbs the supply — perhaps with difficulty around the August 6 unlock — and the IPO window stays open through year-end. The risk case is that a disorderly SpaceX lockup, combined with a deteriorating OpenAI timeline and continued below-IPO-price trading across the H1 cohort, causes the window to narrow. The data so far supports the base case at roughly 65/35, but the August 4-6 period is the specific test that will recalibrate those odds. If the largest lockup expiration in history passes without a disorderly tape, the structural case for continued issuance holds. If it does not, the pipeline behind it — Anthropic, the rolling SpaceX tranches, the follow-on calendar — faces a much heavier lift.